The Bloomberg~Kimmel Institute for Cancer Immunotherapy led by Dr. Drew Padroll is at the forefront of discovering and developing new immune-based cancer treatments. The institute builds on pioneering discoveries, many here at Johns Hopkins, that are making it possible to trigger the immune system’s innate cancer-fighting abilities. The JHDD plays an integral part of the Bloomberg~Kimmel Institute for Cancer Immunotherapy by serving as its Drug Discovery and Development Core, which provides a broad range of expertise in drug discovery research to translate findings from basic and clinical research into novel cancer immunotherapy.